A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction
The Three Generations of Incretin Peptide Research The progression from single to dual to triple agonist peptides represents a research trajectory that has played out in roughly ten years: Generation 1 Single GLP-1 Agonists (Semaglutide, Liraglutide, Exenatide) The first incretin peptides to reach broad clinical research were GLP-1 receptor agonists
Estos medicamentos imitan los efectos de la hormona natural pero con duracin extendida, lo que permite su uso teraputico en diabetes tipo 2 y obesidad.
However, we also acknowledge that liraglutide is also available as a once-weekly injection
Its worth pointing out that while compounded might sound like something experimental, in reality its a well-established practice in medicine that ensures patients get access to treatments made carefully and responsibly
